Structured BioEquity's (SBE's) innovative financial product enables sustainability for clinical-stage biotechnology companies by offering an insurance policy on the high attrition rate of Phase II therapeutic drug candidates. SBE's STanDaRD (Sustainability for the FuTure of DRug Development) product…
Structured BioEquity's (SBE's) innovative financial product enables sustainability for clinical-stage biotechnology companies by offering an insurance policy on the high attrition rate of Phase II therapeutic drug candidates. SBE's STanDaRD (Sustainability for the FuTure of DRug Development) product transfers technical risk to the capital markets at the time in a drug candidate's lifecycle when the greatest amount of uncertainty is traded for the greatest amount of enterprise value. SBE is a technology-enabled company applying a proven risk-transfer model in the $15.6B market of "alternative risk transfer" to create a new market for drug development risk. SBE acts as a managing general agent for insurance collateral funds - SBE is not a hedge fund. Our mission is to create and market innovative financing solutions that allow biotechnology companies to prevent and treat the most crucial unmet medical needs. www.structuredbioequity.com
Team (1)
Sectors Structured BioEquity, Inc. serves:
Financial Services
Life Sciences
Join Axial's Private M&A Platform
Structured BioEquity, Inc. connects with qualified M&A advisors through the Axial Platform.
Looking for Buyers?
Reach this investor and hundreds more on Axial. No cost to advisors.
